A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy Subjects
Latest Information Update: 28 Apr 2025
At a glance
- Drugs SHR-1816 (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Beijing Suncadia Pharmaceuticals
Most Recent Events
- 20 Apr 2025 Status changed from not yet recruiting to discontinued because sponsor has changed internal strategy.
- 22 Apr 2022 New trial record